Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients
CLINICAL LABORATORY, vol.65, no.11, pp.2079-2089, 2019 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 65 Issue: 11
- Publication Date: 2019
- Doi Number: 10.7754/clin.lab.2019.190343
- Journal Name: CLINICAL LABORATORY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.2079-2089
- Keywords: tacrolimus, CYP3A5, ABCB1, polymorphism, pharmacokinetics, SINGLE-NUCLEOTIDE POLYMORPHISMS, TROUGH CONCENTRATION, DOSE REQUIREMENTS, DRUG-INTERACTIONS, EARLY-STAGE, PHARMACOKINETICS, CYTOCHROME-P450, CYCLOSPORINE, METABOLISM, MDR1
- Eskisehir Osmangazi University Affiliated: Yes
Abstract
Background: Tacrolimus (Tac) is a calcineurin inhibitor (CNI). Its therapeutic range is narrow and pharmacokinetic properties vary among patients. CYP3A5 and MDR1 single-nucleotide polymorphisms (SNPs) are the most effective polymorphisms that play an significant role in the pharmacokinetics of Tac.